Now approved for first-line maintenance treatment regardless of biomarker status1
Zejula is indicated as monotherapy for the maintenance treatment of adult patients with advanced epithelial (FIGO Stages III and IV) high-grade ovarian, fallopian tube or primary peritoneal cancer who are in response (complete or partial) following completion of first-line platinum-based chemotherapy.1*
Proven efficacy regardless of biomarker status
A safety and tolerability profile consistent with previous clinical trial experience1-3
88% of women in the overall population remained on Zejula therapy without discontinuations due to AEs1,2
Side effects can be managed with dose interruption and modification.
- AEs led to dose interruptions and reduction in 80% of patients, most frequently from thrombocytopenia (56%), anaemia (33%), and neutropenia (20%).
Individualised Zejula dosing reduced haematological AEs and maintained PFS vs a fixed starting dose1, 4-6
- For patients weighing <77 kg OR with a platelet count <150,000/ uL, the recommended dose is 200mg taken orally once daily.1
- For patients weighing ≥77 kg AND a platelet count ≥150,000/uL, the recommended dose is 300 mg taken orally once daily.1
PRIMA- Impact of individualised dosing on adverse events5
Convenient, once-daily oral dosing1
200mg is the recommended starting dose for patients with moderate hepatic impairment (regardless of bodyweight).1,7
Adverse events should be reported. Reporting forms and information can be found at https://yellowcard.mhra.gov.uk/ or search for MHRA Yellowcard in the Google Play or Apple App store. Adverse events should also be reported to GlaxoSmithKline on 0800 221 441.
© 2020 GSK Group of Companies or its licensor.
Trademarks are the property of their respective owners.
July 2021 | PM-GB-NRP-WCNT-210006